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Background: Australia was one of the first countries to introduce a publicly funded national human papillomavirus
(HPV) vaccination program that commenced in April 2007, using the quadrivalent HPV vaccine targeting 12- to
13-year-old girls on an ongoing basis. Two-year catch-up programs were offered to 14- to 17- year-old girls in
schools and 18- to 26-year-old women in community-based settings. We present data from the school-based
program on population-level vaccine effectiveness against cervical abnormalities in Victoria, Australia.
Methods: Data for women age-eligible for the HPV vaccination program were linked between the Victorian
Cervical Cytology Registry and the National HPV Vaccination Program Register to create a cohort of screening
women who were either vaccinated or unvaccinated. Entry into the cohort was 1 April 2007 or at first Pap test for
women not already screening. Vaccine effectiveness (VE) and hazard ratios (HR) for cervical abnormalities by
vaccination status between 1 April 2007 and 31 December 2011 were calculated using proportional hazards
regression.
Results: The study included 14,085 unvaccinated and 24,871 vaccinated women attending screening who were
eligible for vaccination at school, 85.0% of whom had received three doses. Detection rates of histologically
confirmed high-grade (HG) cervical abnormalities and high-grade cytology (HGC) were significantly lower for
vaccinated women (any dose) (HG 4.8 per 1,000 person-years, HGC 11.9 per 1,000 person-years) compared with
unvaccinated women (HG 6.4 per 1,000 person-years, HGC 15.3 per 1,000 person-years) HR 0.72 (95% CI 0.58 to
0.91) and HR 0.75 (95% CI 0.65 to 0.87), respectively. The HR for low-grade (LG) cytological abnormalities was 0.76
(95% CI 0.72 to 0.80). VE adjusted a priori for age at first screening, socioeconomic status and remoteness index,
for women who were completely vaccinated, was greatest for CIN3+/AIS at 47.5% (95% CI 22.7 to 64.4) and 36.4%
(95% CI 9.8 to 55.1) for women who received any dose of vaccine, and was negatively associated with age. For
women who received only one or two doses of vaccine, HRs for HG histology were not significantly different from
1.0, although the number of outcomes was small.
Conclusion: A population-based HPV vaccination program in schools significantly reduced cervical abnormalities
for vaccinated women within five years of implementation, with the greatest vaccine effectiveness observed for the
youngest women.* Correspondence: msaville@vcs.org.au
1VCS Inc, 265 Faraday St, Carlton, VIC 3053, Australia
Full list of author information is available at the end of the article
© 2013 Gertig et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Gertig et al. BMC Medicine 2013, 11:227 Page 2 of 12
http://www.biomedcentral.com/1741-7015/11/227Background
Randomized clinical trials have shown that prophylactic
human papillomavirus (HPV) vaccines are highly effec-
tive at preventing infection with HPV types 16 and 18,
which cause about 70 to 80% of cervical cancers world-
wide [1,2] and in preventing related cervical abnorma-
lities, which are the precursors to cervical cancer [3,4].
HPV16 and 18 are detected in about half of all high
grade cervical intraepithelial lesions (CIN2/3), and in an
even higher percentage of CIN2/3 diagnosed in women
under 30 years of age [2,5-7]. Two vaccines are commer-
cially available - a bivalent vaccine targeting HPV types
16 and 18 and a quadrivalent vaccine which also targets
HPV types 6 and 11, responsible for 90% of genital
warts. Types 16/18/6/11 have been detected in about
30% of low-grade cervical cytological abnormalities,
reflecting that these low-grade lesions indicate acute
HPV infection, which can be caused by any of the 40
genital HPV types [8]. The trials showed greatest efficacy
for women naïve to HPV at the time of vaccination, as
the vaccines do not have any therapeutic effect on
targeted HPV types.
These vaccines have been widely adopted in high in-
come countries since 2007 with most countries targeting
girls prior to commencement of sexual activity, between
9 and 13 years of age, with varying catch-up programs
for older adolescent girls [9]. Australia was one of the
first countries to offer a national, publicly funded vaccin-
ation program, using a three-dose schedule of the
quadrivalent vaccine Gardasil©. Commencing in April
2007, the Australian vaccination program targeted 12-
and 13-year-old girls in schools and offered catch-up
vaccination for 14- to 17-year-old girls in schools and
18- to 26-year-old women in community based settings.
Australia is in a unique position to evaluate the impact
of the HPV vaccine at the population level. The
recommended starting age for cervical screening is 18
years or 2 years after the onset of sexual activity, which-
ever is later, and thus screening already overlaps with
the vaccination program. Screening is recommended
every two years using conventional cytology until the
age of 69 years. Australia’s State based Pap test registers
systematically record cervical cytology and histology re-
sults and send reminder and follow-up letters to
women and their practitioners according to national
guidelines. Participation in both screening and vacci-
nation programs is high: catch-up HPV vaccine cove-
rage in Victorian females 12 to 17-years old was 86/
82/75% for doses 1/2/3 (JMLB personal communica-
tion) and 77% of 20 to 24-year-olds attended at least
one screening between 2007 and 2011 [10].
In this retrospective cohort study, we linked data from
the Victorian Cervical Cytology Registry (VCCR) and the
National HPV Vaccination Program Register (NHVPR)and evaluated the effectiveness of the HPV vaccine
against cervical abnormalities in a screening population
of women eligible for vaccination in the school-based
cohorts (aged 17 or younger in 2007). We focus on this
cohort for two reasons: (1) effectiveness in this age
group will most closely approximate the eventual impact
of vaccination in the ongoing target group of girls prior
to sexual activity and (2) vaccination status in the school
cohorts is more completely notified than in the adult
women catch-up program, where notification was not
compulsory and under-notification has been estimated
at 10 to 15% [11].Methods
Data collection
The VCCR captures cervical screening results for all
women resident in Victoria, Australia, which has a
population of more than 2.7 million women, and re-
ceives data on cervical cytology and histopathology di-
rectly from laboratories in a timely manner. Fewer than
1% of women request to opt-off the VCCR [10]. Details
regarding the information held on the VCCR have been
published previously [10]. The VCCR supports the national
screening policy by sending reminders and contacting
women and their practitioners when results of indicated
follow-up tests are not received by the register. Australian
guidelines recommend referral to colposcopy for all women
with a high-grade abnormality suspected or diagnosed
on cytology and for all glandular abnormalities. It is
recommended that women with low grade cytology have
a repeat Pap smear at 12 months, except in women over
30 years of age with an inadequate screening history or
when two consecutive low-grade abnormalities have been
reported [12].
The NHVPR was established in June 2008 and records
HPV vaccination doses administered nationwide. Details
on the establishment of the NHVPR, and initial coverage
in both the schools program and the catch-up program
have been published elsewhere [11,13,14]. In brief, doses
administered through schools are received from school
immunization providers, which are predominantly local
councils and health departments, and notification from
these providers is believed to be virtually complete.
Doses administered in the school programs prior to
register establishment were also systematically uploaded
to the register.Data linkage
Cross-referencing of data against cervical cytology regis-
ters for monitoring of the effectiveness of HPV vaccine
is allowed for by legislation enabling operation of the
NHVPR. However, because the VCCR was established
far earlier, there is no similar provision for the VCCR
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data linkage in this study.
A deterministic linkage procedure was undertaken to
link records from the VCCR, which included Victorian
women who are age-eligible for the HPV vaccine as per
product indication (date of birth on or after 1 July 1962),
to the NHVPR which included all Australian women
who received the HPV vaccine prior to 1 January 2012
(Figure 1).
At the time of extraction, data from the VCCR and
NHVPR were de-identified in the same manner. Ran-
domly generated record ID numbers were assigned to
women in each register. The Data Linkage Unit gene-
rated a series of 22 linkage keys using combinations of
variables, such as selected letters from given name andAustralian Institute of Health
Data Linkag
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Figure 1 Data linkage process and exclusions for analysis.surname, perturbed date of birth, postcode and parts of
the Medicare number. The quality of these linkage keys
was assessed by calculating the percentage of unique
combinations each would be likely to produce. The first
16 linkage keys produced a set of unique combinations
with the best balance between incorrectly accepting a
given record pair as the same person versus failing to
accept a given record pair as the same person, and these
were used to link records in a deterministic manner.
Study design and inclusion criteria
A retrospective cohort was constructed of women aged
17 or younger in 2007 who had a Pap test recorded on
the VCCR during the study period, 1 April 2007 (the
date the HPV vaccination program commenced) to 31 and Welfare (AIHW)
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Number of observations 14,085 24,871 1,422 2,268 21,151
Mean age in 2007 16.1 (± 1.0) 16.0 (± 1.0)* 16.0 (± 1.0) 16.0 (± 1.0)# 16.0 (± 1.0)
Mean age at first screen 18.5 (± 1.4) 18.5 (± 1.3)# 18.1 (± 1.5)# 18.1 (± 1.5)# 18.6 (± 1.3)
Mean age at entry to cohort 19.0 (± 1.4) 19.0 (± 1.3) 18.7 (± 1.3)# 18.7 (± 1.3)# 19.0 (± 1.2)#
Age in 2007 (years)
≤14 1,446 (10.3%) 2,567 (10.3%) 163 (11.5%) 271 (11.9%)* 2,131 (10.1%)
15 2,434 (17.3%) 4,480 (18.0%) 262 (18.4%) 470 (20.7%)# 3,743 (17.7%)
16 4,125 (29.3%) 7,419 (29.8%) 372 (26.2%)+ 628 (27.7%) 6,413 (30.3%)*
17 6,080 (43.2%) 10,405 (41.8%)+ 625 (44.0%) 899 (39.6%)+ 8,864 (41.9%)*
Remoteness area3
Major cities 10,019 (71.8%) 16,608 (66.8%)# 955 (67.2%)# 1,477 (65.1%)# 14,154 (67.0%)#
Inner regional 3,250 (23.3%) 6,858 (27.6%)# 383 (26.9%)# 642 (28.3%)# 5,826 (27.6%)#
Outer regional 681 (4.9%) 1,380 (5.6%)+ 83 (5.8%) 147 (6.5%)# 1,149 (5.4%)+
Remote 6 (0.0%) 14 (0.1%) 1 (0.1%) 2 (0.1%) 11 (0.1%)
Socioeconomic status4
1 (lowest) 2,551 (18.4%) 3,830 (15.5%)# 278 (19.6%) 401 (17.7%) 3,147 (14.9%)#
2 2,833 (20.4%) 4,741 (19.1%)+ 336 (23.7%)+ 497 (22.0%)* 3,899 (18.5%)#
3 2,713 (19.6%) 4,463 (18.0%)# 262 (18.5%) 444 (19.7%) 3,754 (17.8%)#
4 3,195 (23.1%) 6,340 (25.6%)# 302 (21.3%) 572 25.3%)+ 5,461 (25.9%)#
5 (highest) 2,571 (18.6%) 5,399 (21.8%)# 240 (16.9%) 346 (15.3%)# 4,804 (22.8%)#
Age at first screen (years)
≤14 105 (0.7%) 114 (0.5%)# 13 (0.9%) 30 (1.3%)+ 71 (0.3%)#
15 to 17 2,831 (20.1%) 4,840 (19.5%) 436 (30.7%)# 624 (27.5%)# 3,775 (17.8%)#
18+ 11,149 (79.2%) 19,917 (80.1%)* 973 (68.4%)# 1,614 (71.2%)# 17,305 (81.8%)#
Screening history
Screening before 1 April 2007 244 (1.7%) 385 (1.5%) 52 (3.7%)# 74 (3.3%)# 257 (1.2%)#
First screen after 1 April 2007 13,841 (98.3%) 24,486 (98.5%) 1,370 (96.3%)# 2,194 (96.7%)# 20,894 (98.8%)#
Age commenced vaccination (years)
≤13 591 (2.4%) 19 (1.3%)! 63 (2.8%) 509 (2.4%)
14 to 15 9,609 (38.6%) 318 (22.4%)$ 756 (33.3%)$ 8,526 (40.3%)
16 to 17 13,519 (54.4%) 679 (47.7%)$ 1,159 (51.1%)$ 11,665 (55.2%)
18+ 1,152 (4.6%) 406 (28.6%)$ 290 (12.8%)$ 451 (2.1%)
Year entered cohort
2007 632 (4.5%) 497 (2.0%)# 46 (3.2%)* 52 (2.3%)# 398 (1.9%)#
2008 1,114 (7.9%) 2,140 (8.6%)* 188 (13.2%)# 248 (10.9%)# 1,701 (8.0%)
2009 2,350 (16.7%) 4,924 (19.8%)# 357 (25.1%)# 577 (25.4%)# 3,982 (18.8%)#
2010 3,981 (28.3%) 7,375 (29.7%)+ 403 (28.3%) 607 (26.8%) 6,361 (30.1%)#
2011 6,008 (42.7%) 9,935 (39.9%)# 428 (30.1%)# 784 (34.6%)# 8,709 (41.2%)+
Cytological abnormalities diagnosed on entry into cohort5
Negative 11,444 (82.7%) 19,661 (85.4%)# 911 (80.5%)# 1,579 (84.1%)# 17,148 (85.7%)
Low-grade 1,817 (13.1%) 2,488 (10.8%)# 169 (14.9%) 230 (12.2%)# 2,086 (10.4%)#
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Table 1 Summary of descriptive characteristics of cohort (Continued)
High-grade
Possible 111 (0.8%) 146 (0.7%)* 8 (0.7%) 15 (0.8%) 123 (0.6%)*
Definite 97 (0.7%) 132 (0.6%)* 12 (1.1%) 12 (0.6%) 108 (0.5%)*
Endocervical 1 (0.0%) 4 (0.0%) 0 (0.0%) 0 (0.0%) 4 (0.0%)
1Count is of women; “unvaccinated” refers to women screened who did not receive any dose of HPV vaccine; “completely vaccinated” refers to women who were
clinically completely vaccinated with three doses of HPV vaccine.
2Entry into the cohort was at first Pap test, or 1 April 2007 if screened before this date.
3Women were allocated to a remoteness area based on their postcode of usual residence, according to the Australian Standard Geographic Classification (ASGC)
for 2006. Missing data on 140 women excluded.
4Women were allocated to a socioeconomic status (SES) groups based on their postcode of usual residence, according to the Australian Bureau of Statistics Socio-
Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage [17]. Missing data on 320 women excluded.
5Missing data on 2,079 women excluded.
*P-value P ≤0.05 (reference group unvaccinated women).
+P-value ≤0.01 (reference group unvaccinated women).
#P-value ≤0.001 (reference group unvaccinated women).
$P-value ≤0.001 (reference group fully vaccinated women). Note any dose group not compared.
!P-value ≤0.01 (reference group fully vaccinated women). Note any dose group not compared.
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diagnosis of a cervical abnormality from the time they
commenced cervical screening, and were entered into
the cohort at their first Pap test (or on 1 April 2007 if
their first Pap test was prior to that time). We found
that our analyses were robust when the entry criteria
to the cohort for those screening prior to April 2007
were altered to include person-time from their first
Pap test after 1 April 2007. Women were followed until
the outcome of interest, date of death, hysterectomy or
the end of the study period.Assignment of vaccination status
Unvaccinated women were those who had no doses of
HPV vaccine recorded on the NHVPR; vaccinated women
were those who received any doses of HPV vaccine. Com-
pletely vaccinated women were those vaccinated with three
doses compliant with the vaccine schedule (and, if doses
were closer than recommended minimum intervals, where
no further doses were recommended according to Chief
Medical Officer guidelines. Women with further doses
needed according to the guidelines were excluded from
the analyses (n = 25) [15]. Person-time and events were
allocated to each “woman-dose” according to her vac-
cination dates. For unvaccinated women, person-time com-
menced from the date of first Pap test as above. For
vaccinated women, a new vaccination status (number of
doses) was assigned on the date of that dose and
person-time at that dose number was included until re-
ceipt of a further dose (if any). Where screening and
vaccination occurred on the same day, if a screening-
related outcome was diagnosed on that test, the woman’s
vaccination status for that outcome was assigned to
her vaccination status during the period immediately
prior to that date (dose delivered -1); hence, prevalent
abnormalities were assigned to the relevant vaccin-
ation status.We chose the dose assignment method, with no time-
lag until abnormalities are ‘counted’ after vaccination,
because we wanted to reflect apparent incident abnor-
malities as they occurred in the real world (that is, what
the patient and clinician would experience after vaccin-
ation as a measure of vaccine effectiveness). However,
we recognize that abnormalities diagnosed during the
vaccination course are predominantly caused by HPV
infection acquired prior to the onset of vaccination.
Therefore, we also evaluated the cohort using a mea-
sure closer to vaccine efficacy assessment, excluding
time for vaccinated women where they were in the
process of being vaccinated, that is, censoring time oc-
curring between dose 1 and dose 3. This second
method (presented in the Additional file 1: Table S1)
counts person-time according to the woman’s final
vaccination status and thus only includes person-time
for partial vaccination where this was the woman’s
final vaccination status. This will more closely reflect
the actual efficacy of receipt of only one or two doses.
Definition of outcomes
The primary outcome was histologically confirmed high-
grade (HG) cervical disease (CIN2+/AIS), defined as CIN2,
CIN3, adenocarcinoma in situ or mixed CIN3/AIS. Histo-
logical and cytological outcomes were assigned according
to categorization used by the AIHW [12] and Australian
Standardised Modified Bethesda System, respectively [16].
For all outcomes, a woman’s first relevant abnormality or
her first in two years with at least two negative cytology
tests in between, were counted. Abnormalities diagnosed
on the first test were included as incident abnormalities.
Statistical methods
Analyses of demographic and exposure characteristics of
women in the cohort by vaccination status used the Mann-
Whitney U test for ordinal variables and the Pearson chi-
square test for nominal variables. Detection rates were
Table 2 Number and rate of cervical abnormalities for completely vaccinated, partially vaccinated and unvaccinated
women
Outcome No. women-doses No. abnormalities Rate* Hazard ratio
Histological abnormalities
Any high grade Unvaccinated 15,192 138 6.4 1.0
Vaccinated (unadjusted) 0.76 (0.61 to 0.95)
Vaccinated (adjusted) 27,179 181 4.8 0.72 (0.58 to 0.91)
1 dose 2,568 27 9.7 1.47 (0.97 to 2.23)
2 doses 3,412 28 6.8 1.02 (0.68 to 1.53)
1 or 2 doses 5,980 55 8.0 1.20 (0.88 to 1.65)
Complete 21,199 126 4.1 0.61 (0.48 to 0.78)
CIN3/AIS Unvaccinated 15,192 61 2.8 1.0
Vaccinated (unadjusted) 0.68 (0.48 to 0.95)
Vaccinated (adjusted) 27,179 70 1.9 0.64 (0.45 to 0.90)
1 dose 2,568 12 4.3 1.40 (0.75 to 2.61)
2 doses 3,412 11 2.7 0.87 (0.46 to 1.67)
1 or 2 doses 5,980 23 3.3 1.09 (0.67 to 1.76)
Complete 21,199 47 1.5 0.53 (0.36 to 0.77)
CIN2 Unvaccinated 15,192 87 4.0 1.0
Vaccinated (unadjusted) 0.81 (0.61 to 1.06)
Vaccinated (adjusted) 27,179 122 3.2 0.78 (0.59 to 1.03)
1 dose 2,568 16 5.7 1.29 (0.76 to 2.20)
2 doses 3,412 18 4.4 0.99 (0.59 to 1.64)
1 or 2 doses 5,980 34 4.9 1.11 (0.75 to 1.66)
Complete 21,199 88 2.9 0.70 (0.52 to 0.94)
CIN1 Unvaccinated 15,192 163 7.5 1.0
Vaccinated (unadjusted) 0.86 (0.70 to 1.05)
Vaccinated (adjusted) 27,179 244 6.5 0.83 (0.68 to 1.02)
1 dose 2,568 20 7.2 0.89 (0.56 to 1.41)
2 doses 3,412 30 7.3 0.90 (0.61 to 1.33)
1 or 2 doses 5,980 50 7.2 0.90 (0.65 to 1.23)
Complete 21,199 194 6.3 0.82 (0.66 to 1.01)
Cytological abnormalities
High-grade cytology Unvaccinated 15,192 325 15.3 1.0
Vaccinated (unadjusted) 0.77 (0.67 to 0.89)
Vaccinated (adjusted) 27,179 442 11.9 0.75 (0.65 to 0.87)
1 dose 2,568 44 16.0 0.85 (0.62 to 1.17)
2 doses 3,412 67 16.5 0.95 (0.73 to 1.23)
1 or 2 doses 5,980 111 16.3 0.91 (0.73 to 1.13)
Complete 21199 331 10.9 0.71 (0.61 to 0.83)
Low-grade cytology Unvaccinated 15,192 2,306 125.8 1.0
Vaccinated (unadjusted) 0.77 (0.73 to 0.82)
Vaccinated (adjusted) 27,179 3,184 95.3 0.76 (0.72 to 0.80)
1 dose 2,568 250 101.9 0.67 (0.59 to 0.76)
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Table 2 Number and rate of cervical abnormalities for completely vaccinated, partially vaccinated and unvaccinated
women (Continued)
2 doses 3,412 328 89.2 0.64 (0.57 to 0.72)
1 or 2 doses 5,980 578 94.3 0.66 (0.60 to 0.72)
Complete 21,199 2,606 95.5 0.79 (0.75 to 0.84)
*Rate per 1,000 person-years.
All high grade histology defined as CIN2, CIN3, AIS and mixed CIN3/AIS.
High-grade cytology defined as possible high-grade squamous intraepithelial lesion (HSIL), HSIL, HSIL with possible microinvasion/invasion, squamous cell
carcinoma, possible high-grade endocervical glandular lesion, AIS, AIS with possible microinvasion/invasion and adenocarcinoma.
Low-grade cytology defined as possible low-grade squamous intraepithelial lesions (LSIL), LSIL and atypical endocervical cells of uncertain significance.
Unvaccinated refers to women screened who did not receive any dose of HPV vaccine; completely vaccinated refers to women who were clinically completely
vaccinated with three doses of HPV vaccine.
Hazard ratios adjusted for remoteness, SES and age at first screening.
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at risk and vaccine effectiveness was (1-rate ratio) × 100.
Cox proportional hazards regression was used to esti-
mate hazard ratios (HR) and 95% confidence intervals
(CI), and included a priori the other predictors: age at
first screening (as a proxy for age at sexual debut), socio-
economic status and remoteness. Remoteness areas were
assigned based on postcode of residence and as defined
according to the Australian Standard Geographic Classi-
fication. Socioeconomic status was assigned by postcode
of residence according to the Australian Bureau of Sta-
tistic’s Socio-Economic Indexes for Areas (SEIFA) Index
of Relative Socio-Economic Disadvantage [17]. Lower
socioeconomic status is associated with poorer screening
participation and higher cervical cancer incidence in
Australia [12]. Individuals were observed until detection
of outcome or 31 December 2011, whichever occurred
first. All data were analyzed using the Proportional ha-
zards regression (PHREG) procedure using SAS Institute
Inc software, Cary, NC, USA [18].
Ethics approval was obtained from the Department of
Health and Ageing and the Australian Institute of Health
and Welfare’s Human Research and Ethics Committees.
Approval for use of NHVPR data was given by the Depart-
ment of Health and Ageing, the data custodian and for the
VCCR data by the Victorian Department of Health.
Results
Between 1 April 2007 and 31 December 2011, 24,871
women aged between 12 and 17 years who were vaccinated
against HPV had commenced cervical screening. Of these
women, 21,151 (85.0%) were completely vaccinated and
3,690 women had received one or two doses of vaccine.
There were 14,085 unvaccinated women of the same age
who had commenced cervical screening. The follow-up
period was a maximum of 4.8 years with an average of 1.5
years for both vaccinated women and unvaccinated
women. There was no difference in mean age at entry into
the cohort or mean age at first screen between vaccinated
and unvaccinated women, with almost all first Pap tests oc-
curring after April 2007, Table 1. Because the youngestgirls at the time of vaccination were only just becoming eli-
gible for cervical screening at the time of analysis, most
women in the study were vaccinated between 14 and 17
years of age, with a mean age at vaccination of 15.7 years.
Seventy five percent of women in this analysis who com-
pleted the vaccine course received their first dose in 2007,
at the commencement of the Australian HPV vaccination
program, with 20% commencing in 2008 (predominantly
those aged 14 years and under in 2007). Unvaccinated
women were more likely to be from a major city and of
lower socioeconomic status (SES) than vaccinated women.
Partially vaccinated women (one or two doses) were youn-
ger at first screen than either unvaccinated women or vac-
cinated women, much older at vaccine commencement
and of lower socioeconomic status than completely vacci-
nated women (P <0.05).
The number and rate of cervical abnormalities detected
by vaccination status as per our primary analysis (dose as-
signment method for assessing vaccine effectiveness) is
shown in Table 2. A lower risk of any histologically con-
firmed HG cervical abnormality was observed for vacci-
nated women (any dose) compared with unvaccinated
women with a hazard ratio of 0.72 (95% CI 0.58 to 0.91),
after adjusting for age at first screening, SES and remote-
ness. This effect was strongest for completely vaccinated
women; there was no significant reduction among those
partially vaccinated (Table 2), but the number of outcomes
was small. Similarly, detection rates of CIN3/AIS and
CIN2+ were significantly lower for vaccinated women
compared to unvaccinated women during the study
period. There was a reduced risk of LG cytological ab-
normalities for women who received one or two doses
of vaccine HR 0.66 (95% CI 0.60 to 0.72) compared
with unvaccinated women. However, this result was sen-
sitive to the censoring of time during the vaccination
course for fully vaccinated women using our secondary
analytic method (more similar to trial efficacy calcula-
tions) (see Additional file 1: Table S1). There were only
three women in this cohort with outcomes of AIS, one
occurred in a vaccinated woman and two in unvacci-
nated women.
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and vaccination status for each outcome of interest. De-
tection rates for any histological outcomes increased
with age and were lower for women who had receivedFigure 2 Cervical abnormalities rates for vaccinated and unvaccinated w
by age in 2007. (a) (b) CIN 3/AIS histology per 1,000 women years, by age in 2
histology per 1,000 women years, by age in 2007. (e) Low-grade cytology per
women years, by age in 2007. All high grade histology is defined as CIN2,any dose of HPV vaccine compared with unvaccinated
women at all ages. For cytological outcomes, rates were
also lower for vaccinated women at all ages as compared
with unvaccinated women for LG cytology. There was aomen, by age in 2007. High-grade histology per 1,000 women years,
007. (c) CIN 2 histology per 1,000 women years, by age in 2007. (d) CIN I
1,000 women years, by age in 2007. (f) High grade cytology per 1,000
CIN3, AIS and mixed CIN3/AIS. Age is presented in years.
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http://www.biomedcentral.com/1741-7015/11/227suggestion of a reduced risk of HG histology for younger
women who received one or two doses of vaccine rather
than none as compared with older women but the num-
bers were small (data not presented).
Vaccine effectiveness (VE), adjusted for remoteness, SES
and age at first Pap test, was highest for CIN3/AIS at
47.5% (95% CI 22.7 to 64.4) for women who were com-
pletely vaccinated (compared to no doses), (Figure 3a) and
was slightly lower for women who received any dose of
vaccine 36.4% (95% CI 9.8 to 55.1), Figure 3b). VE for
histological outcomes was highest in younger women (that
is, those who were less likely to be sexually active before
vaccination) declining thereafter with increasing age. For
most age groups, VE was lowest for CIN1 outcomes, al-
though it is important to note that in Australia only a
small proportion of LG cytology lesions lead to further
investigation [16]. For HG cytology, adjusted VE for all













































Figure 3 HPV vaccine effectiveness for cervical histological outcome,
vaccine dose. All high-grade histology is defined as CIN2, CIN3, AIS and m
(1-adjusted hazard rate) x 100. Age in years, as of 2007.CI 13.3 to 35.0), similar to that for LG cytology, ad-
justed VE 23.9% (95% CI 19.6 to 27.9).
Discussion
Our results show that quadrivalent HPV vaccination
substantially reduced cervical abnormalities for women
receiving any HPV vaccine dose through a school-based
program, within five years of implementation. Vaccine
effectiveness against high-grade histological disease was
higher than that observed in the intent-to-treat (ITT)
analyses of the clinical trials of the quadrivalent HPV
vaccine, which vaccinated women between the ages of 16
and 25, and was highest in younger women, who as a
group are least likely to have been sexually active prior to
vaccination. Vaccine effectiveness was greatest for out-
comes most strongly associated with vaccine related
HPV types 16 and 18, in particular CIN3/AIS, and lowest






























by age in 2007, for (a) completed vaccine course, for (b) any
ixed CIN3/AIS. Vaccine effectiveness is defined as
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types. The reduction in risk of cervical abnormalities was
restricted to women who received three doses of vaccine.
The follow-up time in our study was five years and
further follow-up will likely impact upon the effective-
ness of the vaccine. Our data confirm that VE dimi-
nishes with age of administration in catch-up programs,
which is a proxy for the onset of sexual activity. The on-
going vaccination programs in Australia and elsewhere
target girls prior to onset of sexual debut and at the
population level higher reductions will be observed as
this large cohort reaches screening age, as a greater pro-
portion of vaccinated women will have been unexposed
to HPV at the time of vaccination. The VE was higher in
the youngest women in our study than observed in the
ITT analyses of either the quadrivalent or bivalent vac-
cine trials [19-21]. The VE from ITT analyses, at an ave-
rage of 3.6 years follow-up, for the quadrivalent vaccine
irrespective of HPV type was 16.4% 95% CI (0.4 to 30.0),
rate reduction 0.2 for CIN3, compared with 45.3% (95%
CI 29.8 to 57.6), rate reduction 0.3, for the analyses re-
stricted to disease related to vaccine types [3,22]. For the
bivalent vaccine, the VE for CIN3 at four years end of
study follow-up was similar for TVC analyses related to
HPV 16 and 18 endpoints 45.7% (95% CI 22.9 to 62.2),
rate reduction 0.13, as compared with endpoints irre-
spective of HPV type VE 45.6% (95% CI 28.8 to 58.7),
rate reduction 0.22 [20].
Studies have shown that a greater proportion of
CIN3+ lesions in younger women (under 30 years of
age) is due to HPV type 16, with other less oncogenic
types more prevalent in women over 30 years of age
[5-7]. HPV16 is likely to overwhelmingly predominate as
a cause of high-grade disease in women aged under 20,
which is the age group at screening of the youngest
women in our study (age 14 years in 2007). It is also
possible that the intensive surveillance of the trial popu-
lations detected more non-HPV16/18 related CIN than
occurs in real world screening programs, where many of
these abnormalities will develop and resolve within the
screening interval and are thus never observed. This
could explain why a larger percentage of disease appears
to be prevented in the population setting than in the
trial setting. The predominance of HPV16 related dis-
ease in younger women has implications for the post-
vaccination surveillance of high-grade lesions, as a
greater impact of the vaccine may be expected initially.
As vaccinated cohorts age and span a broader age range
that includes women in their 30s, where other less onco-
genic HPV types are more prevalent and may take lon-
ger to progress, the impact of vaccination on the overall
CIN3+ burden may be relatively reduced [2,12].
We observed a significant impact of vaccination on LG
cytological abnormalities that was similar in magnitudeto that observed for HG cytological lesions. In addition,
the effect of partial vaccination was significant for LG cy-
tology, but not for HG cytology, although this may be
due to the larger number of outcomes in this group. Be-
cause a greater proportion of HG cytology is due to
vaccine-related HPV types than LG cytology, we would
have expected to see a greater impact on HG as com-
pared with LG cytological lesions. However, this result
was sensitive to whether we counted person-time in
between dose one to three for those women who
ended up being fully vaccinated (see Additional file 1:
Table S1). Abnormalities occurring during this period
are likely to be a result of pre-existing HPV infection
due to the short time frame between doses, but we be-
lieve that this reflects the real world vaccine effective-
ness in the population. Two meta-analyses showed
that the contribution of HPV16 and 18 worldwide in
LSIL lesions is approximately 34% [8,23] while in
CIN3, it is approximately 57% [23], with some regional
variation. Recent Australian data show a relatively high
proportion, approximately 41%, of LG cytological le-
sions contain HPV types 16/18/6/11 in women aged
25 years and under (personal communication JMLB)
and this may also in part explain our observed reduc-
tion in LG cytological abnormalities.
There are several potential limitations of our analysis.
We did not have a complete date of migration out of
Victoria and there may be a small degree of loss to
follow-up on the VCCR. The data linkage for this ana-
lysis was conducted according to accepted protocols;
although some inaccuracies are an inherent part of
the linkage methodology, the effect of this is likely to
be small [24]. Any under-reporting of doses to the
NHVPR given in the community to women who were
within the school cohort, or doses given to women who
opt-off the register, would have biased results towards
the null if a proportion of unvaccinated women were
truly vaccinated. Follow-up time was limited due to the
recency of screening commencement among women
vaccinated at school.
As this is an observational study, rather than a ran-
domized study, women who chose to be vaccinated are
likely to be different from those who are not vaccinated.
Women of lower socioeconomic status were somewhat
less likely to be vaccinated in our study, although results
were unchanged in the adjusted analysis. Uncontrolled
confounding by other factors may also have influenced
the magnitude of the observed impact of the vaccine.
However, as only women who had ever had a Pap test
are included in this analysis, the effect of any
sociodemographic factors that cause both lower vaccin-
ation coverage and screening uptake (for example, being
a member of a culturally and linguistically diverse group)
is minimized.
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tection against disease, vaccine programs could achieve
higher coverage at a lower cost [25-27]. There are sev-
eral possible explanations as to why we did not observe
a protective effect of one or two doses. Notably, women
who only received one or two doses of vaccine rather
than the full course were younger at first screening
(suggesting earlier sexual debut), older at vaccination
and of lower socioeconomic status. Adjusting for age at
first screening and SES may mitigate somewhat but can-
not completely control for the underlying differences in
this group of women, who appear to be more likely to
have been infected prior to vaccination than the fully
vaccinated group. Analysis including more women, vac-
cinated prior to sexual debut and taking into account
underlying sociodemographic differences among women
who do not complete the course, is needed to refine the
estimates of impact against disease for partially vacci-
nated women.
Our results contribute to the growing body of evi-
dence in Australia of a reduced burden of HPV-related
disease since implementation of the vaccination program
in 2007. Data from HPV prevalence studies show a sig-
nificant reduction in the prevalence of vaccine HPV ge-
notypes (6, 11, 16, 18) in a post-vaccination sample
compared with a pre-vaccination sample and lower
prevalence in both vaccinated and unvaccinated women
compared with the pre-vaccine reference population
[28]. A substantial impact of the HPV vaccine on genital
warts has already been observed in Australia, with a de-
cline by the end of 2009 of 59% in warts diagnosed at
sexual health services among women in the target age
group (26 and under in 2007), and a smaller decline of
28% among heterosexual men of similar age [29]. A
similar decline in the incidence of genital warts has been
reported in New Zealand, the United States and Sweden
[30-33]. Ecologic data [34] and routine monitoring
data [10,12] show significant declines in histologically
confirmed high-grade cervical abnormalities since the
Australian vaccination program commenced among
women under 20 years of age. In 2011 we demonstrated
an absolute decrease in incidence of high-grade cervical
abnormalities in Victoria of 0.38% (CI 95% 0.61 to 0.16)
for women under 18 years of age [34]. The main limitation
of these analyses was that individual level data on vac-
cination status were not available and thus it was not
possible to attribute the decline in disease solely to the
vaccination program.
Conclusions
In conclusion, we have demonstrated the first population
level impact of a school-based HPV vaccination program
on cervical abnormalities. The program included a two-
year catch-up for girls aged 14- to 17-years and achievedhigh vaccination coverage rates. The impact of the vaccine
was greatest for women completely vaccinated at younger
ages and for the more serious cervical abnormalities
CIN3/AIS, which are more likely to be due to the vaccine
HPV types. The reduction in risk of cervical abnormalities
was restricted to women who received three doses of vac-
cine; however, relatively few women received fewer than
three doses and these women were older at vaccination
than the other women. Over the next five years, the effect
of the vaccine is expected to increase as cohorts of women
vaccinated prior to sexual debut move through the scree-
ning program.
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Additional file 1: Table S1. Rate of histological and cytological cervical
abnormalities for completely vaccinated, partially vaccinated and
unvaccinated women using final dose status method (secondary analysis
using ‘efficacy’ method).
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